top of page

PMS and Vigilance: Post-Market Surveillance

The post-market surveillance (PMS) system, the Annex III surveillance plan, the Class I surveillance report, PSUR frequency and vigilance reports, for devices registered in ÜTS.

A hospital calls, describes an incident involving a device you sold, and you have no written procedure showing where to report it, within what time and in what capacity. Or, during a notified body audit, you are asked to "show your PMS plan" and the only document you have is a complaint form of a few pages. A third situation is more common still: you have a Class IIa product and you do not know whether you need to prepare a PSUR and, if so, how often to update it.

This page deals with post-market surveillance and vigilance separately. It sets out what a surveillance system and a plan are, the minimum scope the plan must have under Annex III, the distinction between the post-market surveillance report and the periodic safety update report by class, the time limits written in the Regulation for reporting serious incidents and field safety corrective actions, the trend reporting obligation, and to whom each actor in the chain reports, with article references.

The sources are the Medical Device Regulation (Tıbbi Cihaz Yönetmeliği) published in the Official Gazette No. 31499 (bis) of 2/6/2021, Annex III of the same Regulation, and the Regulation on the Sales, Advertising and Promotion of Medical Devices (Tıbbi Cihaz Satış, Reklam ve Tanıtım Yönetmeliği) published in the Official Gazette No. 29001 of 15/5/2014. The numbers of days given below are not estimates; they are the time limits written in the Regulation, given together with their articles.

The surveillance system is not a separate folder, it is part of the quality system

The most common design mistake is to set up post-market surveillance as a file separate from the quality system. Article 81(1) of the Medical Device Regulation says that manufacturers, for each device, plan, establish, document, implement, maintain and update a post-market surveillance system in a manner that is proportionate to the risk class and appropriate for the type of device, and that this system is an integral part of the manufacturer's quality management system referred to in Article 10(9).

This link does not run in one direction only. Point (ğ) of Article 10(9) says that the quality management system will include, as a minimum, the matters concerning the establishment, implementation and maintenance of the post-market surveillance system under Article 81; point (ı) says it will include the processes for reporting serious incidents and field safety corrective actions within the scope of vigilance. Article 10(10) says that manufacturers will implement and keep up to date the post-market surveillance system under Article 81; Article 10(13) says that manufacturers will have a system for recording and reporting incidents and field safety corrective actions as set out in Articles 85 and 86.

What the system must be able to do is also defined. Article 81(2) says that the system must be suited to actively and systematically gathering, recording and analysing relevant data on the quality, performance and safety of a device throughout its lifetime; to drawing the necessary conclusions; and to determining, implementing and monitoring preventive and corrective actions. The word "actively" is decisive here: waiting for a complaint to arrive does not meet this paragraph.

Where the collected data will be used is listed

Collecting data and keeping it in a folder does not meet the obligation either. Article 81(3) lists the purposes for which, in particular, the data gathered through the surveillance system will be used: updating the benefit-risk determination and improving risk management as referred to in Chapter I of Annex I; updating design and manufacturing information, the instructions for use and the labelling; updating the clinical evaluation; updating the summary of safety and clinical performance referred to in Article 32; identifying needs for preventive, corrective or field safety corrective action; identifying options to improve the usability, performance and safety of the device; where relevant, contributing to the post-market surveillance of other devices; and detecting and reporting trends under Article 86. The same paragraph ends with one sentence: the technical documentation is updated accordingly.

This last sentence is the source of a question often asked in audits. If you have collected data from the market but the instructions for use, the risk file and the clinical evaluation have stayed the same, either the data has produced no meaningful finding and the reason for this is written down, or the paragraph has not been met.

Article 81(4) also sets an action obligation: if a need for corrective or preventive action, or both, is identified during surveillance, manufacturers take the appropriate measures and inform the Agency, the other competent authorities concerned and, where there is one, the notified body. The same paragraph defines the transition from surveillance to vigilance by saying that, when a serious incident is identified or a field safety corrective action is implemented, it is reported under Article 85.

The surveillance plan rests on point 1 of Annex III

The system and the plan are not the same thing. Article 82(1) of the Regulation says that the post-market surveillance system referred to in Article 81 will be based on a post-market surveillance plan whose requirements are set out in point 1 of Annex III, and that, for devices other than custom-made devices, this plan will be part of the technical documentation specified in Annex II.

The opening of Annex III says that the technical documentation on post-market surveillance to be drawn up by the manufacturer under Articles 81 to 84 will be presented in a clear, organised, readily searchable and unambiguous manner. Point 1 of Annex III says that the manufacturer will demonstrate in the post-market surveillance plan that it complies with the obligation in Article 81.

Which information the plan will address is listed in point 1(a) of Annex III: information on serious incidents and field safety corrective actions, including information from periodic safety update reports; records referring to non-serious incidents and data on any undesirable side-effects; information from trend reporting; relevant specialist or technical literature, databases and/or registers; information, including feedback and complaints, provided by users, distributors and importers; and publicly available information about similar medical devices.

Minimum scope of the plan

Point 1(b) of Annex III lists what the plan will cover as a minimum. This list is a criterion that can be used directly to test whether a PMS plan is adequate.

  • Proactive collection process: a proactive and systematic process to collect the information referred to in point (a); this process allows an accurate characterisation of the performance of the devices and makes it possible to compare the device with similar products on the market.

  • Assessment methods: effective and appropriate methods and processes to assess the data collected.

  • Indicators and threshold values: suitable indicators and threshold values used in the continuous reassessment of the benefit-risk analysis and of risk management as referred to in point 3 of Annex I.

  • Complaint investigation tools: effective and appropriate methods and tools to investigate complaints and analyse market-related experience collected in the field.

  • Trend methodology: methods and protocols to manage incidents subject to trend reporting as provided for in Article 86, including the methods and protocols to be used to establish any statistically significant increase in the frequency or severity of incidents, as well as the observation period.

  • Communication protocols: methods and protocols to communicate effectively with competent authorities, notified bodies, economic operators and users.

  • References to procedures: reference to procedures to fulfil the manufacturer's obligations laid down in Articles 81, 82 and 84.

  • Starting measures: systematic procedures to identify and initiate appropriate measures, including corrective actions, and effective tools to trace and identify devices for which corrective action might be necessary.

  • Clinical follow-up: a post-market clinical follow-up plan as referred to in Part B of Annex XIV, or a justification as to why post-market clinical follow-up is not applicable.

The last item is the one most often found missing in audits. A plan either contains the clinical follow-up plan or carries the justification for why it does not; a plan that contains neither does not meet this point.

Point 2 of Annex III says that the second element of the technical documentation on surveillance is the periodic safety update report referred to in Article 84 and the post-market surveillance report referred to in Article 83.

Surveillance report in Class I, PSUR in Class IIa and above

The report type differs by class, and this distinction is made in two separate articles.

Article 83(1) of the Regulation says that manufacturers of Class I devices will prepare a post-market surveillance report summarising the results and conclusions of the analysis of the data gathered in line with the plan in Article 82, together with the rationale for and a description of any preventive and corrective actions taken. The same paragraph says that this report will be updated when necessary and made available to the Agency upon request. No fixed update frequency is provided for Class I; the criterion is "when necessary".

Point (a) of Article 84(1) of the Regulation says that manufacturers of Class IIa, Class IIb and Class III devices will prepare, for each device and, where relevant, for each category or group of devices, a periodic safety update report summarising the results and conclusions of the analysis of the data gathered in line with the plan, together with a rationale for and description of any preventive and corrective actions taken.

The same point adds that the report will set out, throughout the lifetime of the device concerned, three things: the conclusions of the benefit-risk determination, the main findings of the post-market clinical follow-up, and the volume of sales of the device together with an estimate of the size and other characteristics of the population using the device and, where practicable, the usage frequency of the device. The sales volume item is the one most often left out on the ground that it is commercial information; the point asks for it expressly.

The update frequency of the PSUR varies by class

Point (b) of Article 84(1) says that manufacturers of Class IIb and Class III devices will update the periodic safety update report at least once a year, and that this report will be part of the technical documentation as specified in Annexes II and III, except for custom-made devices.

Point (c) of the same paragraph says that manufacturers of Class IIa devices will update the periodic safety update report when necessary and at least every 2 years, and that this report too will be part of the technical documentation as specified in Annexes II and III, except for custom-made devices. Point (ç) says that, for custom-made devices, the report will be part of the documentation referred to in point 2 of Annex XIII.

Note the words "at least" here: one year or two years is not a ceiling but a floor. When a finding appears that changes the benefit-risk determination, you have no justification for waiting.

To whom the PSUR is submitted

Article 84(2) says that, for Class III devices or implantable devices, manufacturers will submit periodic safety update reports through the electronic system referred to in Article 89 to the notified body involved in the conformity assessment under Article 52. The same paragraph says that the notified body will review the report and add its evaluation, with details of any action taken, to that electronic system, and that these reports and evaluations will be made available to the Agency and the other competent authorities through that system.

The third paragraph sets out a different route for other devices: for these devices, manufacturers submit periodic safety update reports to the notified body involved in the conformity assessment and, upon request, to the Agency and the other competent authorities. In other words, for Class III and implantable devices submission is regular and through the system; for the others it is submission to the notified body, with a further submission to the Agency depending on its request.

What a serious incident is, and what must be reported

Arguing about time limits is pointless without knowing the definition. Point (ı) of Article 3 of the Regulation defines a serious incident as any incident that directly or indirectly led, might have led or might lead to the death of a patient, user or other person, the temporary or permanent serious deterioration of a person's state of health, or a serious public health threat. Point (nn) of the same article defines an incident as any malfunction or deterioration in the characteristics or performance of a device made available on the market, including use errors due to ergonomic features, as well as any inadequacy in the information supplied by the manufacturer and any undesirable side-effect.

On the field side there are two concepts. Point (zz) defines a field safety corrective action as a corrective action taken by the manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market; point (yy) defines a field safety notice as a communication sent by the manufacturer to users or customers in relation to a field safety corrective action.

What is to be reported is listed in Article 85(1). Point (a) says that manufacturers of devices made available on the market, except investigational devices, will report any serious incident involving the devices; expected side-effects that are clearly documented in the product information, quantified in the technical documentation and subject to trend reporting under Article 86 are excluded from this reporting. Point (b) says that any field safety corrective action in respect of devices made available lawfully on the market in Türkiye or in EU member states, including actions undertaken outside these countries, will be reported; the case where the reason for the action is limited to a device on the market of countries outside Türkiye and the European Union is excluded.

Reporting time limits written in the Regulation

Article 85(2) says that, as a general rule, the severity of the serious incident will be taken into account in the time limits for reporting. The following paragraphs tie this principle to three concrete time limits.

  • Fifteen days: Paragraph 3 says that manufacturers will report a serious incident immediately after they have established a causal relationship between the incident and their device, or that such a relationship is reasonably possible, and that this period will not exceed 15 days after the manufacturers become aware of the incident.

  • Two days: Paragraph 4 says that, notwithstanding paragraph 3, in the event of a serious public health threat the report will be submitted immediately, and not later than 2 days after the manufacturer becomes aware of the threat.

  • Ten days: Paragraph 5 says that, notwithstanding paragraph 3, in the event of death or an unanticipated serious deterioration in a person's state of health the report will be submitted immediately after the manufacturer has established or suspects a causal relationship between the device and the incident, and not later than 10 days after it becomes aware of the incident.

All three paragraphs tie the time limit to the moment of "becoming aware". For this reason your complaint record should contain not only the date but the moment of becoming aware, with the time; the clock starts there.

Paragraph 6 provides some flexibility: where necessary to ensure timely reporting, the manufacturer may submit an initial report before a complete report. Paragraph 7 resolves the case of doubt: after becoming aware of a potentially reportable incident, the manufacturer submits a report within the time frame required by paragraphs 2 to 5 even if it is not certain whether the incident is reportable. In other words, uncertainty is not a ground for not reporting.

A field safety corrective action is reported first, then carried out

Article 85(8) says that, except in urgent cases where the manufacturer needs to undertake a field safety corrective action immediately, the manufacturer will report the action referred to in point (b) of paragraph 1 without delay before undertaking it. The order is thus: apart from an urgent case, the report comes before the action.

The notice that reaches the user is a separate obligation. Point (a) of Article 87(8) says that the manufacturer will ensure that information about the field safety corrective action is brought without delay to the attention of the users of the device through a field safety notice, and that the notice will be drawn up in Turkish and/or in the official EU language or languages determined by the EU member states in which the action is taken. The same point adds that, except in urgent cases, the content of the draft notice will be submitted to the Agency or the coordinating competent authority to allow it to comment, and that, unless duly justified, the content of the notice will be the same in Türkiye and in all EU member states.

Point (b) sets criteria for the content of the notice: the notice allows the correct identification of the device or devices, in particular by including the relevant UDIs, and of the manufacturer that undertook the action, by including its single registration number if already issued; it clearly explains the reasons for the action, with reference to the device malfunction and the associated risks to patients, users or other persons, without understating the level of risk; and it clearly indicates all actions to be taken by users. Point (c) says that the manufacturer will enter the field safety notice in the electronic system referred to in Article 89, and that the notice will thereby be made accessible to the public.

Trend reporting is a separate and independent obligation

An event not being counted as a serious incident does not mean it will never be reported. Article 86(1) of the Regulation says that manufacturers will report, through the electronic system in Article 89, any statistically significant increase in the frequency or severity of incidents that are not serious incidents or that are expected undesirable side-effects, which have or may have a significant impact on the benefit-risk analysis referred to in points 1 and 8 of Annex I and which give rise or may give rise to risks to the health or safety of patients, users or other persons that are unacceptable when weighed against the intended benefits.

The same paragraph also defines how this increase is determined: a significant increase is determined by comparison with the foreseeable frequency or severity of such incidents in relation to the device, or category or group of devices, over a specific period, as stated in the technical documentation and product information. The last sentence of the paragraph ties the matter to the plan: the manufacturer specifies in the post-market surveillance plan referred to in Article 82 how it will manage these incidents and the methodology used to determine a statistically significant increase, together with the observation period.

The practical consequence is this: you cannot set your threshold values after the incident. The methodology and the observation period must be written in the plan before the incident. Article 86(2) says that the Agency may carry out its own assessment of the trend reports and may require the manufacturer to take appropriate measures to protect public health and patient safety.

After the report, an investigation, and a final report at the end

Reporting does not end the process. Article 87(1) of the Regulation says that, following the reporting of a serious incident, the manufacturer will without delay perform the necessary investigations in relation to the incident and the devices concerned, and that these investigations will include, as appropriate, a risk assessment of the incident and the field safety corrective action. The same paragraph says that the manufacturer will cooperate with the Agency, the competent authorities concerned and, where relevant, the notified body concerned during the investigation, and that it will not perform any investigation that involves altering the device or a sample of the batch concerned in a way that may affect a subsequent evaluation of the causes of the incident, prior to informing the Agency and the other competent authorities. Do not dismantle the sample you hold without telling the Agency; the paragraph expressly prohibits this.

Article 87(5) says that the manufacturer will submit a final report stating its findings from the investigation to the competent authority concerned through the electronic system in Article 89, and that this report will state the conclusions reached and, where relevant, the corrective actions to be taken. Article 87(4) says that the Agency will monitor the manufacturer's investigation of the serious incident and, where necessary, may intervene in the investigation or initiate an independent investigation. Article 87(3) lists the criteria the Agency will take into account in its assessment and provides that manufacturers will submit all documents necessary for the risk assessment upon the Agency's request.

There is an easing for repeated similar incidents. Article 85(9) says that, for similar serious incidents occurring with the same device or device type where the root cause has been identified, a field safety corrective action has been implemented, or the incidents are common and well documented, periodic summary reports may be submitted instead of individual reports, provided that the coordinating competent authority agrees with the manufacturer on the format, content and frequency of the periodic summary reporting. This is not an exemption; it is a form of reporting that depends on agreement.

Article 88 of the Regulation regulates the opposite direction: where a previously unknown risk is identified, or where the frequency of an anticipated risk significantly and adversely changes the benefit-risk determination, the Agency or, where appropriate, the coordinating competent authority informs the manufacturer or, where there is one, the authorised representative, who is to take the necessary corrective actions.

Who reports to whom

What gets confused most often in vigilance is which link in the chain reports to whom. The Medical Device Regulation and the Sales, Advertising and Promotion Regulation deal with this separately.

  • Manufacturer: reports to the Agency and the other competent authorities concerned, through the electronic system in Article 89, under Article 85(1).

  • Authorised representative: Article 11(3)(f) requires it to inform the manufacturer without delay about complaints and reports from healthcare professionals, patients and users on suspected incidents relating to the device for which it is appointed; point (e) requires it to cooperate with the competent authorities in any corrective or preventive action taken to eliminate or mitigate the risks.

  • Importer: Article 13(8) says that importers who receive complaints or reports from healthcare professionals, patients or users about suspected incidents relating to a device they have placed on the market will forward this information without delay to the manufacturer and the authorised representative. Paragraph 6 requires a register to be kept of complaints, non-conforming devices, recalls and withdrawals.

  • Distributor: Article 14(5) says that complaints and reports of suspected incidents will be forwarded without delay to the manufacturer and, where there is one, the authorised representative and importer, and that records of complaints, non-conforming devices, recalls and withdrawals will be kept.

  • Sales centre: Article 31(1) of the Regulation on the Sales, Advertising and Promotion of Medical Devices says that sales centres will report incidents they encounter during their activities, relating to their own devices or other devices, to the Agency and to the manufacturer or importer of the device concerned without delay. Article 10(9) of the same Regulation says that the Responsible Manager will report incidents reported in relation to the devices sold to the Agency and to the manufacturer or importer of the device concerned without delay. Article 11(4)(c) and Article 12(6) provide that sales and promotion staff and clinical support staff will forward incidents reported to them to the Responsible Manager without delay.

  • Healthcare professional, user and patient: Article 85(10) says that suspected serious incidents will be reported to the Agency by healthcare professionals, users and patients, and that the Agency will record these reports centrally.

The return path from the Agency to the manufacturer is also defined. Article 85(11)(a) says that, if the Agency receives such reports, it will take the necessary steps to ensure that the manufacturer of the device concerned is informed without delay. Article 85(11)(b) says that, if the manufacturer considers the incident serious, it will submit a report under paragraphs 1 to 5 and carry out the follow-up under Article 87; Article 85(11)(c) says that, if the manufacturer does not consider the incident serious or considers it an expected undesirable side-effect under Article 86, it will submit an explanatory statement, and that, if the Agency does not agree with this assessment, it may require the manufacturer to submit a report and carry out the follow-up.

Through which system the reports go, and when the provisions enter into force

Article 89(1) of the Regulation lists what information the electronic system set up by the Commission on vigilance and post-market surveillance will contain: the reports on serious incidents and field safety corrective actions under Articles 85(1) and 87(5), the periodic summary reports under Article 85(9), the trend reports under Article 86, the periodic safety update reports under Article 84, the field safety notices under Article 87(8), and the information to be exchanged between the competent authorities and the Commission.

Paragraphs 4, 5 and 6 of the same article say that serious incident reports, trend reports and field safety corrective action reports will be automatically transmitted to the competent authorities concerned upon receipt; paragraph 8 says that this information will also be automatically transmitted to the notified body that issued the certificate for the device concerned under Article 56. Paragraph 3 states that healthcare professionals and the public will be given appropriate levels of access to the system.

There is a detail on the entry-into-force side that should not be skipped. Article 111(1)(a) of the Regulation says that, as regards the obligations and requirements associated with each of the electronic systems referred to in Article 33(2), the provisions including Article 84(2), Articles 85 and 86, Article 87(5) and (7), Article 87(8)(c) and Article 88 will enter into force 6 months after the date of publication in the Official Journal of the European Union of the notice by the Commission that the electronic system concerned is functional and meets the functional specifications.

This does not mean that reporting disappears. Articles 81 to 83 and paragraphs 10 and 13 of Article 10 are not listed within the scope of this point; the obligations to set up the surveillance system, prepare the plan, have a reporting system and reflect the data in the technical documentation are not tied to this point. What is tied to it is the obligations on submitting certain reports through the electronic system concerned.

What changes on the ÜTS side

Article 34(1) of the Regulation says that, without prejudice to the EUDAMED-related obligations laid down in the Regulation, economic operators, notified bodies, health institutions, healthcare professionals and other persons concerned that are established in Türkiye will fulfil their obligations relating to the national product tracking system for medical devices; paragraph 2 says that these obligations will be determined by the regulations published by the Agency.

On the vigilance side, the function of ÜTS is traceability. Article 25(2) of the Regulation requires economic operators to be able to identify to the Agency, for the period referred to in Article 10(8), every economic operator to whom they have directly supplied a device, every economic operator who has directly supplied them, and every health institution or healthcare professional to which they have directly supplied a device. This is the record that will show which batch went where when you start a field safety corrective action. Article 31(3) of the Sales, Advertising and Promotion Regulation also says that sales centres will keep the details of the previous and, where there is one, the next economic operator in the supply chain in an orderly manner on the basis of parameters such as batch, serial, lot, brand and model, and will keep these records for at least ten years from the date they start making the device available on the market.

The Agency's own side is also defined. Article 90(1) of the Regulation says that the Agency will carry out appropriate checks on the conformity of the characteristics and performance of devices and will in particular take into account established principles on risk assessment and risk management, vigilance data and complaints. Your vigilance records are not only your own file; they are an input to market surveillance and inspection activity.

What we do on PMS and vigilance, and who carries the obligation

Within Medical Device ÜTS Registration Consultancy, our outputs on this subject are as follows:

  • Plan gap analysis: We compare your existing post-market surveillance plan with the items in points 1(a) and 1(b) of Annex III and report the headings that are missing and, in particular, whether a clinical follow-up plan or its justification is present.

  • Report type determination: For each device in your product list, we determine whether a post-market surveillance report under Article 83 or a periodic safety update report under Article 84 is needed, and the update frequency under point (b) or (c).

  • Time limit map: We build the 15, 2 and 10 day time limits in Article 85(3), (4) and (5) into your internal procedure, from recording the moment of becoming aware through to sending the report.

  • Trend thresholds: We make sure that the methodology, observation period and threshold values required by Article 86(1) are written in the surveillance plan.

  • Reporting flow: We put the reporting chain between manufacturer, authorised representative, importer, distributor and sales centre in writing according to Articles 11, 13 and 14 and Articles 10 and 31 of the Sales, Advertising and Promotion Regulation.

  • Traceability check: We test whether the supply chain information in Article 25(2) can be drawn from your ÜTS individual-item movement records.

What we cannot do is also clear. We do not file a serious incident report on your behalf; Article 85(1) ties this obligation to the manufacturer, and Article 11(4) says that the post-market surveillance obligation in Article 10(10) cannot be transferred even by an authorisation document. The final decision on whether an event is a serious incident comes from the manufacturer's risk assessment; we do not stand in for that decision. We cannot produce the benefit-risk analysis, the clinical evaluation or the risk file in place of the manufacturer. Nor do we give any commitment on how and when the Agency will conclude a vigilance file.

Our way of working on the ÜTS side is this: the firm assigns us a user authorisation from its own ÜTS firm page, and we create and update device and document records with the "Medical Device Registration Operator" ("Tıbbi Cihaz Kayıt Elemanı") authorisation. The person who signs the application electronically remains the firm's signatory; the vigilance obligation likewise stays with the firm.

For the minimum scope of the PMS plan, the PMS report, the PSUR content and the update frequency by class, see our guide page on the PSUR and post-market surveillance.

Tıbbi Cihaz ÜTS Kayıt Danışmanlığı

Request an ÜTS registration consultancy quote

Ehlibeyt Mahallesi, Tekstilciler Caddesi No: 35/7 06520 Çankaya / Ankara - TÜRKİYE

Cevizli Mahallesi, Zuhal Caddesi Ritim İstanbul B Blok, No:44 Maltepe / İstanbul - TÜRKİYE

info@medexmedikal.com
+90 505 580 4622
+90 312 389 1354

ÜTS Guides · Legislation Calendar · Glossary · ÜTS Guide Index · Frequently Asked Questions

Services: ÜTS Consultancy · Who Carries Out the ÜTS Registration? · ÜTS Document Registration Consultancy · ÜTS Product Registration Consultancy · Importer ÜTS Registration Consultancy · Sales Centre Authorisation Certificate · EUDAMED Registration Consultancy · MDR/IVDR Declaration of Conformity · Technical File Preliminary Review · Label and Instructions for Use Check · PRRC Service · PMS and PSUR · Clinical Evaluation · EMDN and GMDN Code Determination · Certificate of Free Sale · EUDAMED XML Generator · ÜTS Registration Training · Correction of a Rejected ÜTS Application

KVKK and Privacy Policy | Cookie Policy | Accessibility Statement

© 2026 Medex Kurumsal Danışmanlık Ltd. Şti.

bottom of page
WhatsApp Hemen Ara